All the Drug Class Drugs
anti-GD2(MAB). Dinutuximab Beta 4.5 mg/ml. VIAL: 1×4.5 mg/ml. Dosage must be ajust. individ.
Tmt. of high-risk neuroblastoma in pts. aged 12 mnths. and above, who have previously received induct. chemother. and achieved at least a part. response, follow. by myeloablative therapy and stem cell transplant., as well as pts. with history of relapsed or refract. neuroblastoma, with/without residual dis. Prior to the tmt. of relapsed neuroblastoma, any actively progress. dis. should be stabilised by other suitable measures.
In pts. with a history of relapsed/refractory dis. and in pts. who have not achieved a complete response after 1st line ther. Dinutuximab beta should be combin. with interleukin-2 (IL-2).
C/I: Hypersens. Acute grade 3 or 4, or extensive chron. graft-versus-host disease (GvHD).
